Unknown

Dataset Information

0

Improvement in plasma drug activity during the early treatment interval among Tanzanian patients with multidrug-resistant tuberculosis.


ABSTRACT:

Background

Individual pharmacokinetic variability may be common in patients treated for multidrug-resistant tuberculosis (MDR-TB) but data are sparse from resource-limited settings and across the early treatment interval.

Methods

Plasma drug activity, as measured by the TB Drug Activity (TDA) assay at 2 and 4 weeks of treatment with a standardized MDR-TB regimen was performed in patients with pulmonary MDR-TB from Tanzania. TDA values were correlated with measures of early treatment outcome including every two week collection of sputum for time-to-positivity (TTP) in liquid culture from the MGIT 960 automated system. Patients were evaluated at 24 weeks and those surviving without delayed sputum culture conversion (>8 weeks), culture reversion after previously negative, or weight loss were defined as having a favorable outcome.

Results

Twenty-five patients were enrolled with a mean age of 37 ±12 years. All were culture positive from the pretreatment sputum sample with a mean TTP in MGIT of 257 ±134 hours, and the median time to culture conversion on treatment was 6 weeks. Twenty patients (80%) had an increase in TDA, with the overall mean TDA at 2 weeks of 2.1 ±0.7 compared to 2.4 ±0.8 at 4 weeks (p = 0.005). At 2 weeks 13 subjects (52%) had a TDA value > 2-log killing against their own M. tuberculosis isolate compared to 17 subjects (68%) at 4 weeks (McNemar's exact test p = 0.29). An interim treatment outcome was able to be determined in 23 patients (92%), of whom 7 had a poor outcome (30%). An increase in TDA from week 2 to week 4 was associated with favorable outcome, [unadjusted OR = 20.0, 95% CI: 1.61-247.98, exact p = 0.017 and adjusted OR = 19.33, 95% CI: 1.55-241.5, exact p = 0.023].

Conclusions

The majority of patients with MDR-TB in Tanzania had an increase in plasma drug activity from week 2 to week 4 of treatment as measured by the TDA assay. Understanding the etiology and full impact of this dynamic may inform therapeutic intervention.

SUBMITTER: Ndusilo ND 

PROVIDER: S-EPMC4376785 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

altmetric image

Publications

Improvement in plasma drug activity during the early treatment interval among Tanzanian patients with multidrug-resistant tuberculosis.

Ndusilo Norah D ND   Heysell Scott K SK   Mpagama Stellah G SG   Gratz Jean J   Segesela Farida H FH   Pazia Saumu J SJ   Wang Xin-Qun XQ   Houpt Eric R ER   Kibiki Gibson S GS  

PloS one 20150327 3


<h4>Background</h4>Individual pharmacokinetic variability may be common in patients treated for multidrug-resistant tuberculosis (MDR-TB) but data are sparse from resource-limited settings and across the early treatment interval.<h4>Methods</h4>Plasma drug activity, as measured by the TB Drug Activity (TDA) assay at 2 and 4 weeks of treatment with a standardized MDR-TB regimen was performed in patients with pulmonary MDR-TB from Tanzania. TDA values were correlated with measures of early treatme  ...[more]

Similar Datasets

| S-EPMC2630755 | biostudies-literature
| S-EPMC3421551 | biostudies-literature
| S-EPMC3086214 | biostudies-literature
| S-EPMC4521689 | biostudies-other
| S-EPMC5495008 | biostudies-other
| S-EPMC4184341 | biostudies-literature
| S-EPMC5740303 | biostudies-literature
| S-EPMC4451908 | biostudies-other
| S-EPMC6988333 | biostudies-literature
| S-EPMC7045844 | biostudies-literature